Maris 2023: Masana kimiyyar da suka kirkiro wani sabon magani wanda zai iya yin tasiri ga kowane nau'in ciwon daji na kashi na farko a cikin yara sun kira shi "mafi mahimmancin gano magunguna a fagen cikin kusan rabin karni."
Gwaje-gwaje akan berayen da aka dasa tare da kansar ƙashi na ɗan adam sun nuna ikon CADD522 na hana ƙwayar ƙwayar cuta da ke da alaƙa da ikon yada kansa.
The findings, which were published in the Journal of Bone Oncology, demonstrated, according to the researchers, that the drug can increase survival rates by 50% without the need for surgery or chemotherapy.
Lead researcher Dr Darrell Green, from the University of East Anglia’s Norwich Medical School, said: “Primary ciwon daji na kashi is a type of cancer that begins in the bones.
Wannan ci gaban yana da matukar mahimmanci saboda maganin kansar kashi bai canza ba sama da shekaru 45.
Dr Darrell Green
"Wannan shi ne na uku mafi yawan cutar kansar yara, bayan kwakwalwa da koda, tare da kusan 52,000 sabbin kamuwa da cuta a duk shekara a duk duniya.
“Yana iya bazuwa cikin sauri zuwa sauran sassan jiki, kuma wannan shine mafi yawan matsalolin irin wannan nau'in ciwon daji.
"Da zarar ciwon daji ya yadu, zai zama da wahala a bi da shi da niyyar warkewa."
A halin yanzu, chemotherapy da yanke gaɓoɓi sune kawai maganin kansar kashi, tare da damar 42% na rayuwa.
A cewar masu binciken, "magungunan nasu" yana ƙara yawan rayuwa da kashi 50 cikin XNUMX kuma ba su da mummunan sakamako na chemotherapy, irin su asarar gashi, gajiya, da rashin lafiya.
Masu binciken sun yi nazari kan samfuran ciwon kashi daga marasa lafiya 19 a asibitin Royal Orthopedic da ke Birmingham don manufar binciken.
Sun gano cewa kwayar halittar RUNX2 tana aiki ne a cikin kansar kashi na farko kuma yana da alaƙa da yaduwar cutar.
Dangane da gwaje-gwaje, CADD522 yana hana furotin RUNX2 haɓaka haɓakar ciwon daji.
Dokta Green ya ce, “An ƙaru da rayuwa ba tare da metastasis ba da kashi 50% a cikin gwaje-gwaje na musamman lokacin da aka gudanar da sabon maganin CADD522 shi kaɗai, ba tare da chemotherapy ko tiyata ba.
“Ina da kwarin gwiwa cewa hade da sauran jiyya kamar tiyata, wannan adadi na rayuwa zai kara karuwa.
"Mahimmanci, saboda RUNX2 gene ba yawanci ake buƙata ta sel na al'ada ba, maganin ba ya haifar da lahani kamar chemotherapy.
Tun da maganin ciwon daji na kashi bai canza ba a cikin shekaru 45, wannan binciken yana da mahimmanci.
According to the researchers, the drug is currently undergoing toxicology testing, after which the team will seek approval from the MHRA (Medicines and Healthcare products Regulatory Agency) to begin a gwajin gwaji akan mutane.
Masana kimiyya daga Jami'ar Sheffield, Jami'ar Newcastle, asibitin Royal Orthopedic na Birmingham, da Norfolk da Asibitin Norwich suma sun shiga cikin binciken, wanda Sir William Coxen Trust da Big C.
Dokta Green ya bayyana cewa mutuwar babban abokinsa daga ciwon daji na ƙashi yana ƙarfafa shi ya yi nazarin cutar.
"Ina so in fahimci tushen ilimin halitta na cutar kansa ta yadda za mu iya shiga tsakani a matakin asibiti kuma mu samar da sababbin jiyya don kada marasa lafiya su bi abin da abokina Ben ya yi," in ji shi.
